Inter‐observer agreement of tumor infiltrating lymphocytes in primary <scp>HER2</scp> ‐positive breast cancer and correlation between tissue microarray and full tumor‐sections-Reference-Cited by-同舟云学术

Inter‐observer agreement of tumor infiltrating lymphocytes in primary HER2 ‐positive breast cancer and correlation between tissue microarray and full tumor‐sections

Published:2022-06-26 Issue:9 Volume:130 Page:545-550
ISSN:0903-4641
Container-title:APMIS
language:en
Short-container-title:APMIS

Author:

Reznitsky Frances Mary¹²,Jensen Jeanette Dupont³,Knoop Ann⁴,Laenkholm Anne‐Vibeke¹

Affiliation:

1. Department of Surgical Pathology Zealand University Hospital Roskilde Denmark

2. Department of Pathology Herlev and Gentofte Hospital Herlev Denmark

3. Department of Oncology Odense University Hospital Odense Denmark

4. Department of Oncology Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark

Funder

Zealand University Hospital

Publisher

Wiley

Subject

Microbiology (medical),General Medicine,Immunology and Allergy,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apm.13251

Reference35 articles.

1. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group

2. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

4. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer

5. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer;Acta Oncologica;2023-11-14